Identification of Lynch syndrome among patients with colorectal cancer

JAMA

Volumn 308, Issue 15, 2012, Pages 1555-1565

  Moreira, Leticia ^a   Balaguer, Francesc ^a   Lindor, Noralane ^b   De La Chapelle, Albert ^c   Hampel, Heather ^c   Aaltonen, Lauri A ^d   Hopper, John L ^e   Le Marchand, Loic ^f   Gallinger, Steven ^g   Newcomb, Polly A ^h   Haile, Robert ⁱ   Thibodeau, Stephen N ^b   Gunawardena, Shanaka ^b   Jenkins, Mark A ^e   Buchanan, Daniel D ^j   Potter, John D ^h   Baron, John A ^k   Ahnen, Dennis J ^l   Moreno, Victor ^a   Andreu, Montserrat ^m   De Leon, Maurizio Ponz ⁿ   Rustgi, Anil K ^o   Castells, Antoni ^a   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b MAYO CLINIC   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF HAWAII   (United States)

^g CANCER CARE ONTARIO   (Canada)

^h Fred Hutchinson Cancer Research Center   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^k UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^m UNIVERSITAT POMPEU FABRA   (Spain)

ⁿ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; COLORECTAL CANCER; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GERM LINE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PATIENT IDENTIFICATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR IMMUNOLOGY;

EID: 84867499525     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.13088     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Vasen HF, Boland CR. Progress in genetic testing, classification, and identification of Lynch syndrome. JAMA. 2005;293(16):2028-2030.
3. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348(10):919-932.
4. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35):5783-5788.
5. Stoffel EM, Chittenden A. Genetic testing for hereditary colorectal cancer: challenges in identifying, counseling, and managing high-risk patients. Gastroenterology. 2010;139(5):1436-1441.
6. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999;116(6):1453-1456.
7. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96(4):261-268.
8. Piñol V, Castells A, Andreu M, et al; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005;293(16):1986-1994.
9. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851- 1860.
10. Boland CR, Shike M. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology. 2010;138(7):2197,e1-e7.
11. Balmaña J, Stockwell DH, Steyerberg EW, et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA. 2006;296(12):1469-1478.
12. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354(26):2751-2763.
13. Chen S, Wang W, Lee S, et al; Colon Cancer Family Registry. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA. 2006;296(12):1479-1487.
14. Wijnen JT, Vasen HF, Khan PM, et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer.NEngl JMed. 1998;339(8):511-518.
15. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338(21):1481-1487.
16. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18(11):2193-2200.
17. Newcomb PA, Baron J, Cotterchio M, et al; Colon Cancer Family Registry. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2331-2343.
18. Breast and colon cancer family registries. National Cancer Institute. http://epi.grants.cancer.gov/CFR/. Accessed September 25, 2012.
19. Cicek MS, Lindor NM, Gallinger S, et al. Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population-and clinic-based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn. 2011;13(3):271-281.
20. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination ofmicrosatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248-5257.
21. Baldi P, Brunak S, Chauvin Y, Andersen CA, Nielsen H. Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics. 2000;16(5):412-424.
22. Therneau TM, Atkinson B. R port. http://CRAN.R-project.org/package=rpart. Accessed September 21, 2012.
23. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34(5):424-425.
24. Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 1995;64(6):430-433.
25. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med. 2003;138(7):560-570.
26. Loughrey MB, Waring PM, Tan A, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary nonpolyposis colorectal cancer. Fam Cancer. 2007;6(3):301-310.
27. Rodríguez-Moranta F, Castells A, Andreu M, et al; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: proposal of a new and simpler set of recommendations. Am J Gastroenterol. 2006;101(5):1104-1111.
28. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006;296(12):1507-1517.
29. Wu Y, Berends MJ, Mensink RG, et al. Association of hereditary nonpolyposis colorectal cancerrelated tumors displaying low microsatellite instability with MSH6 germline mutations. Am J Hum Genet. 1999;65(5):1291-1298.
30. Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Cost-effectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med. 2001;135(8 pt 1):577-588.
31. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011;155(2):69-79.
32. Bessa X, Ballesté B, Andreu M, et al; Gastrointestinal Oncology Group of Spanish Gastroenterological Association. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin GastroenterolHepatol. 2008;6(2):206-214.
33. Domingo E, Niessen RC, Oliveira C, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene. 2005;24(24):3995-3998.
34. Payá A, Alenda C, Pérez-Carbonell L, et al. Utility of p16 immunohistochemistry for the identification of Lynch syndrome. Clin Cancer Res. 2009;15(9):3156-3162.
35. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet. 2012;49(3):151-157.
36. Balaguer F, Balmaña J, Castellví-Bel S, et al; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients. Gastroenterology. 2008;134(1):39-46.
37. Kastrinos F, Steyerberg EW, Mercado R, et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology. 2011;140(1):73-81.
38. Kastrinos F, Syngal S. Inherited colorectal cancer syndromes. Cancer J. 2011;17(6):405-415.
39. Balmaña J, Balaguer F, Castellví-Bel S, et al; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J Med Genet. 2008;45(9):557-563.